Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer

In 2018, dosing regimens of the two most prescribed immune check point inhibitors (ICI), nivolumab (Opdivo(®)) and pembrolizumab (Keytruda(®)), in the treatment of lung cancer were changed from weight-based dosing to fixed dosing. The aim of this study was to compare the economic impact of this chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Monirul, Sanjana, Rigal, Marthe, Chouahnia, Kader, Le Jouan, Mélisande, Apparuit, Maxime, Paix, Adrien, Jacolot, Anne, Zelek, Laurent, Duchemann, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761677/
https://www.ncbi.nlm.nih.gov/pubmed/33287161
http://dx.doi.org/10.3390/vaccines8040730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761677/
https://www.ncbi.nlm.nih.gov/pubmed/33287161
http://dx.doi.org/10.3390/vaccines8040730

Ejemplares similares